Literature DB >> 7733080

Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis.

W J Sandborn1, C J Landers, W J Tremaine, S R Targan.   

Abstract

BACKGROUND: Perinuclear antineutrophil cytoplasmic antibodies, present in 60% of patients with ulcerative colitis, may be a marker for a genetically distinct subset of patients who develop chronic pouchitis after undergoing ileal pouch-anal anastomosis. The frequency of these antibodies in chronic pouchitis was determined.
METHODS: Four groups were studied: patients who underwent ileal pouch-anal anastomosis for colitis with and without chronic pouchitis, familial polyposis without pouchitis and ileostomy for colitis. Antineutrophil cytoplasmic antibody levels and titers were detected by ELISA, and positive results were confirmed by perinuclear staining with indirect immunofluorescence.
RESULTS: The frequency of perinuclear antineutrophil cytoplasmic antibodies in chronic pouchitis (100%) was significantly greater than in colitis (50%) or familial polyposis (0%) without pouchitis and colitis with an ileostomy (70%); p = 0.00, 0.00, and 0.01, respectively.
CONCLUSIONS: The finding that perinuclear antineutrophil cytoplasmic antibodies occur more frequently in patients with chronic pouchitis raises the possibility that this antibody may mark a genetically distinct subset of ulcerative colitis patients. Further studies are needed to determine whether the presence of this antibody before ileal pouch-anal anastomosis is predictive for later development of chronic pouchitis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7733080

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  23 in total

Review 1.  Diagnostic methodologies: serology, endoscopy, and radiology.

Authors:  T Dassopoulos
Journal:  Curr Gastroenterol Rep       Date:  2001-12

2.  Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.

Authors:  E A Vasiliauskas; L Y Kam; L C Karp; J Gaiennie; H Yang; S R Targan
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

Review 3.  Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Authors:  C Roozendaal; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

Review 4.  Current concept of pathophysiological understanding and natural course of ulcerative colitis.

Authors:  Martin H Holtmann; Peter R Galle
Journal:  Langenbecks Arch Surg       Date:  2004-02-04       Impact factor: 3.445

5.  Current and future role of serogenomics in ulcerative colitis.

Authors:  Mark H Flasar; Raymond K Cross; David B Doman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

6.  Infliximab to Treat Refractory Inflammation After Pelvic Pouch Surgery for Ulcerative Colitis.

Authors:  Orlaith B Kelly; Morgan Rosenberg; Andrea D Tyler; Joanne M Stempak; A Hillary Steinhart; Zane Cohen; Gordon R Greenberg; Mark S Silverberg
Journal:  J Crohns Colitis       Date:  2015-12-30       Impact factor: 9.071

7.  Chronic pouchitis after ileal pouch-anal anastomosis for ulcerative colitis: effect on quality of life.

Authors:  Matthias Turina; Connie J Pennington; Jennifer Kimberling; Arnold J Stromberg; Robert E Petras; Susan Galandiuk
Journal:  J Gastrointest Surg       Date:  2006-04       Impact factor: 3.452

8.  Antineutrophil cytoplasmic antibodies in sera from colectomised ulcerative colitis patients and its relation to the presence of pouchitis.

Authors:  M Esteve; J Mallolas; J Klaassen; A Abad-Lacruz; F González-Huix; E Cabré; F Fernández-Bañares; X Bertrán; E Condom; J Martí-Ragué; M A Gassull
Journal:  Gut       Date:  1996-06       Impact factor: 23.059

9.  High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis.

Authors:  P R Fleshner; E A Vasiliauskas; L Y Kam; N E Fleshner; J Gaiennie; M T Abreu-Martin; S R Targan
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

10.  Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease.

Authors:  S J Ott; M Musfeldt; D F Wenderoth; J Hampe; O Brant; U R Fölsch; K N Timmis; S Schreiber
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.